Century Therapeutics (IPSC) Keeps CNTY-813 IND on Track for 4Q 2026
Century Therapeutics (IPSC) announced that its CNTY-813 therapy is on track for IND submission in 4Q 2026, with clinical data expected in 2H 2027. The company also plans to initiate clinical trials for CNTY-308 in 2026. As of September 30, 2026, Century has $174.1 million in cash and investments, providing a runway into 1Q 2029. Joseph Truitt was appointed to the board.
How this was made

The 30-second read
Why it matters
The announced timelines reduce uncertainty around regulatory milestones, which may support the stock modestly.
Market read
Timeline confirmations are positive but lack immediate catalyst strength; likely limited short‑term price impact.
What to watch
Potential competition in iPSC therapies and regulatory scrutiny could affect future outcomes.
Background
Century Therapeutics is a clinical‑stage biotech developing iPSC‑derived therapies for diabetes and CAR‑iT cell cancer treatments.
Ticker impact
Century Therapeutics announced its CNTY-813 IND submission remains on track for Q4 2026 and CNTY-308 trial start planned for 2026.
likely modest upside as investors price in reduced regulatory timing risk
Timeline confirmations are favorable but no new data or financials were disclosed, limiting immediate price move.
Market effects
Adds confidence to the broader cell therapy and iPSC sector timeline expectations.
Limited to US biotech investors.
Minimal, as the news is company‑specific.
Counterpoint
The lack of concrete data may suggest delays; investors could remain cautious.
Key entities
- companyCentury Therapeutics
US‑listed biotech (NASDAQ:CNTY) developing CNTY-813 and CNTY-308 programs.

